Poor response to initial reduction therapy (COP) and combined bone marrow and CNS disease are poor prognostic factors in children with advanced (BM±CNS) B-NHL treated on the international study FAB/LMB96.

被引：0
|
作者：
Cairo, MS
Gerrard, M
Sposto, R
Auperin, A
Pinkerton, R
Michon, J
Perkins, S
Raphael, M
McCarthy, K
Weston, C
Patte, C
机构：
[1] COG, Arcadia, CA USA
[2] UKCCSG, Leicester, Leics, England
[3] SFOP, Paris, France
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
492
引用
收藏
页码：143A / 143A
页数：1
相关论文
共 3 条
  • [1] SURVIVAL IN CHILDREN AND ADOLESCENTS (C plus A) WITH MATURE B-NHL PROGRESSING OR RELAPSING FROM TREATMENT ON FAB/LMB 96: TUMOR BURDEN AND TIME TO RELAPSE ARE POOR PROGNOSTIC FACTORS
    Cairo, Mitchell S.
    Sposto, Richard
    Fan, Jin
    Gerrard, Mary
    Auperin, Anne
    Pinkerton, Ross
    McCarthy, Keith
    Raphael, Martine
    Harrison, Lauren
    Goldman, Stanton
    Patte, Catherine
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 855 - 855
  • [2] Deletion of cranial irradiation and addition of systemic high dose methotrexate and intrathecal chemotherapy results in 70% 4-yr. EFS in children and adolescents with CNS positive B-NHL: Results of International FAB/LMB 96 study
    Cairo, M
    Gerrard, M
    Sposto, R
    Auperin, A
    Pinkerton, R
    Michon, J
    Weston, C
    Perkins, S
    Raphael, M
    McCarthy, K
    Patte, C
    ANNALS OF ONCOLOGY, 2005, 16 : 62 - 62
  • [3] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Goldman, Stanton
    Lynch, James
    Harrison, Lauren
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    BLOOD, 2009, 114 (22) : 48 - 48
1